Literature DB >> 16904437

Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas.

Baohua Gao1, Fanwei Meng, Wei Bian, Jun Chen, Haifeng Zhao, Gang Ma, Benkang Shi, Jianping Zhang, Yuqiang Liu, Zhishun Xu.   

Abstract

OBJECTIVES: To evaluate the diagnostic performances of the pheochromocytoma of the adrenal gland scaled score (PASS) proposed in a previous report and that of a logistic model developed in this investigation.
METHODS: In all 130 patients with malignant or assumed benign pheochromocytomas, 15 predictive variables were observed. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of PASS. The logistic model was developed using the 15 predictive variables. Its performance was evaluated by calculating the area under the ROC curve and comparing it with that of the PASS.
RESULTS: The PASS had the area under the ROC curve of 0.899 (95% confidence interval 0.844 to 0.954). Of the 15 variables entered in the logistic regression analysis, 9 were retained in the model. The area under the ROC curve for the logistic model was 0.983 (95% confidence interval 0.967 to 0.998).
CONCLUSIONS: ROC analysis indicated that the PASS could be used for the diagnosis of malignant pheochromocytomas. The logistic model was able to improve the diagnostic performance of the PASS using a different variable weighting method. We emphasize, however, that a clinical prospective evaluation is needed to confirm their actual value.

Entities:  

Mesh:

Year:  2006        PMID: 16904437     DOI: 10.1016/j.urology.2006.02.019

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

1.  SAGES guidelines for minimally invasive treatment of adrenal pathology.

Authors:  Dimitrios Stefanidis; Melanie Goldfarb; Kent W Kercher; William W Hope; William Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2013-09-10       Impact factor: 4.584

Review 2.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

3.  A Case of Malignant Pheochromocytoma Presenting 7 Years After the Initial Surgery.

Authors:  Larsa Al-Omaishi; Jonathan Babin; Ralph L Corsetti
Journal:  Ochsner J       Date:  2017

Review 4.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

5.  Metastatic pheochromocytoma: does the size and age matter?

Authors:  Tomáš Zelinka; Zdeněk Musil; Jaroslava Dušková; Deborah Burton; Maria J Merino; Dragana Milosevic; Jiří Widimský; Karel Pacak
Journal:  Eur J Clin Invest       Date:  2011-04-01       Impact factor: 4.686

6.  A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis.

Authors:  Jörg Singer; Christian A Koch; Woubet Kassahun; Peter Lamesch; Graeme Eisenhofer; Regine Kluge; Thomas Lincke; Matthias Seiwerts; Gudrun Borte; Katrin Schierle; Ralf Paschke
Journal:  Nat Rev Endocrinol       Date:  2011-09-06       Impact factor: 43.330

Review 7.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 8.  [Grading of neuroendocrine tumors].

Authors:  W Saeger; P A Schnabel; P Komminoth
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

Review 9.  A Guide to Pheochromocytomas and Paragangliomas.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-28

Review 10.  Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.

Authors:  C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2021-03-25       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.